Blair William & Co. IL Buys 9,718 Shares of Mind Medicine (MindMed) Inc. $MNMD

Blair William & Co. IL raised its stake in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) by 77.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,218 shares of the company’s stock after buying an additional 9,718 shares during the period. Blair William & Co. IL’s holdings in Mind Medicine (MindMed) were worth $144,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Palumbo Wealth Management LLC raised its holdings in Mind Medicine (MindMed) by 6.3% during the second quarter. Palumbo Wealth Management LLC now owns 24,043 shares of the company’s stock valued at $156,000 after buying an additional 1,415 shares in the last quarter. Bay Rivers Group bought a new position in Mind Medicine (MindMed) during the second quarter valued at about $75,000. Rhumbline Advisers raised its holdings in Mind Medicine (MindMed) by 7.7% during the first quarter. Rhumbline Advisers now owns 108,457 shares of the company’s stock valued at $634,000 after buying an additional 7,762 shares in the last quarter. AWM Investment Company Inc. raised its holdings in Mind Medicine (MindMed) by 1.3% during the first quarter. AWM Investment Company Inc. now owns 1,208,162 shares of the company’s stock valued at $7,068,000 after buying an additional 15,000 shares in the last quarter. Finally, Ally Bridge Group NY LLC raised its holdings in Mind Medicine (MindMed) by 18.1% during the first quarter. Ally Bridge Group NY LLC now owns 390,143 shares of the company’s stock valued at $2,282,000 after buying an additional 59,868 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors.

Mind Medicine (MindMed) Stock Up 14.6%

MNMD stock opened at $13.65 on Monday. Mind Medicine has a twelve month low of $4.70 and a twelve month high of $13.86. The company has a market cap of $1.04 billion, a PE ratio of -8.92 and a beta of 2.55. The business’s 50-day simple moving average is $10.44 and its 200 day simple moving average is $8.36. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 0.22.

Mind Medicine (MindMed) (NASDAQ:MNMD) last released its earnings results on Thursday, July 31st. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.12). On average, research analysts anticipate that Mind Medicine will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on MNMD. Lifesci Capital upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mind Medicine (MindMed) in a report on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, August 1st. Oppenheimer assumed coverage on shares of Mind Medicine (MindMed) in a research note on Monday, August 4th. They set an “outperform” rating and a $25.00 target price for the company. Finally, Needham & Company LLC set a $28.00 price target on shares of Mind Medicine (MindMed) and gave the company a “buy” rating in a report on Monday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mind Medicine (MindMed) currently has an average rating of “Buy” and a consensus target price of $27.83.

Insider Buying and Selling

In other Mind Medicine (MindMed) news, insider Mark Sullivan sold 11,278 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Thursday, September 25th. The stock was sold at an average price of $9.77, for a total transaction of $110,186.06. Following the sale, the insider directly owned 293,852 shares of the company’s stock, valued at approximately $2,870,934.04. The trade was a 3.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel Karlin sold 7,704 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Thursday, September 25th. The shares were sold at an average price of $9.77, for a total value of $75,268.08. Following the sale, the insider directly owned 430,625 shares in the company, valued at $4,207,206.25. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,779 shares of company stock valued at $437,491 over the last three months. 2.26% of the stock is owned by corporate insiders.

Mind Medicine (MindMed) Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.